

2023 Taipei International Breast Cancer Symposium			
7F, Taipei Nangang Exhibition Center, Hall 2		Sat., September 23, 2023	
Time	Topic	Speaker	Moderator
08:20-08:30	Opening Remark	Shou-Tung Chen	
Young Investigator Presentation			
08:30-08:40	Investigating the Connection Between LSM1 and Energy Metabolism in Breast Cancer through Spatial Transcriptome and Single-Cell RNA Sequencing	Yen-Dun Tzeng	Chen-Hsiang Chang
08:40-08:50	Unveiling the Molecular Mechanism of Endocrine Resistance: Insights from Epigenetic Reprogramming and Coupled Transcription Factors in Estrogen Receptor Positive Breast Cancer	An-Chieh Feng	
08:50-09:00	Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study	Han-Fang Cheng	
Improving Breast Cancer Care: Integrating Immunotherapy and Evidence-Based Management			
09:00-09:30	Immune Checkpoint Inhibitor in Neoadjuvant or Adjuvant Setting for Breast Cancer: the Paradigm Shift	Sibylle Loibl	Yuan-Ching Chang
09:30-10:00	Management of ER+ HER2- mBC: Bringing Together Clinical & Real-World Evidence	Adam M. Brufsky	Dar-Ren Chen
10:00-10:30	Coffee Break		
10:30-11:00	Management of Older Patients with Breast Cancer	Etienne Brain	King-Jen Chang
TBCS-GBCC Joint Session: Controversial Issues in the Management of Local Regional Disease			
11:00-11:15	Management of Ipsilateral Local Recurrence: Surgical View	Han-Byoel Lee	Chao-Ming Hung
11:15-11:30	Management of Ipsilateral Local Recurrence: Radiation Oncology View	Chin-Nan Chu	Huan-Ming Hsu
11:30-11:45	Supraclavicular axillary disease management	Shih-Che Shen	Wen-Hung Kuo
11:45-12:00	Contralateral axillary disease management	Soong June Bae	Frank Fu Ou-Yang
12:00-12:20	Panel Discussion	Kuo-Ting Lee Jun Won Min Chiao Lo Byung Joo Chae	Chin-Yao Lin
Satellite Symposium (1)			
12:20-13:00	Luncheon Symposium Interpret the Role of GnRH Agonist from Clinical Trial into Local Practice in Early Breast Cancer	Ming-Yang Wang	Yao-Jen Chang
13:00-13:20	Break		
Reduce the Risk of Recurrence in HR+HER2- Early Breast Cancer			
13:20-13:50	Reducing the Risk of Recurrence in HR+, HER2- High-Risk Early Breast Cancer	Hiroko Masuda	Ling-Ming Tseng
13:50-14:20	Gene Assay tools to Inform Chemotherapy Benefit in HR+ HER2- Anatomically High Risk Early Breast Cancer	Kevin Kalinsky	Cheng-Ping Yu
14:20-14:50	Exploring the Potential of Ribociclib and Endocrine Therapy in Early Breast Cancer: Findings from the NATALEE Trial	Stephen Chia	Chiun-Sheng Huang
14:50-15:20	Panel Discussion Adjuvant Treatment for HR+ HER2-EBC, More or Less	Hiroko Masuda Kevin Kalinsky Stephen Chia Chin-Sheng Hung Jiun-I Lai	Chun-Yu Liu
15:20-15:50	Coffee Break		
Advancing Breast Cancer Care: Challenges, Innovating Strategies, and Promising Therapies			
15:50-16:20	Current Treatment Strategies for High-Risk Patients with HER2+ Early-Stage Breast Cancer: Can We Improve Clinical Outcomes	Miguel Martin	Shin-Cheh Chen
16:20-16:50	Current Challenges in Treating Patients with HER2 positive Breast Cancer: Leave no Options Behind	Nadia Harbeck	Fang-Ming Chen
16:50-17:20	Shape the Treatment Paradigm of HER2-Low MBC: From Guideline to Clinical Practice	Giuseppe Curigiano	Tsu-Yi Chao
17:20-17:50	Promising New Drugs Development for MBC	Peter Schmid	Ming-Feng Hou

2023 Taipei International Breast Cancer Symposium			
7F, Taipei Nangang Exhibition Center, Hall 2		Sun., September 24, 2023	
Time	Topic	Speaker	Moderator
Oral Presentation			
08:10-08:20	GRK6 recruits the β -Arrestin 2/MAPK/NF- κ B signaling axis for promoting the metastatic progression of triple-negative breast cancer	Wen-Ke Wang	Chi-Cheng Huang
08:20-08:30	A competing risk analysis study of prognosis in patients with HER2-low and HER2-zero breast cancer	Joseph Lin	
08:30-08:40	Exploration of Cuproptosis-Related Hub Genes and Microenvironmental Landscape in Breast Cancer using Integrated Spatial Transcriptome and Single-Cell RNA-Sequencing	Jui-Hu Hsiao	
Innovations in HR+ Breast Cancer: Exploring CDK4/6 Inhibitors, Cellular Profiling, and ADCs			
08:40-09:10	What Can We Expect More from CDK4/6i in Treating HR+HER2-mBC Patient?	Dwan-Ying Chang	Fiona Tsui-Fen Cheng
09:10-09:40	Identification and Characterization of a Proliferative Cell Population in Estrogen Receptor-Positive Metastatic Breast Cancer through Spatial and Single-Cell Transcriptomics	Shiuan Chen	Yen-Shen Lu
09:40-10:10	Novel Approaches in Triple Negative and HR+/HER2- Metastatic Breast Cancer - Anti-Trop2 ADC and Future Development	Amy K. Krie	Hsien-Kun Chang
10:10-10:20	Award Ceremony		
10:10-10:30	Coffee Break		
Navigating Breast Cancer Care: Biomarker Progress, Comprehensive MBC/EBC Management			
10:30-11:00	Progress of Biomarker Development for Breast Cancer	Aleix Prat	Jyh-Cherng Yu
11:00-11:30	Local Regional Management for Patients after Neoadjuvant Therapy	Mehra Golshan	Shyr-Ming Sheen-Chen
11:30-12:00	Managing ER-Positive, HER2-Negative Advanced Breast Cancer, a Long Journey	Junichiro Watanabe	Kun-Ming Rau
12:00-12:30	Early Breast Cancer Therapy Advancements: Pegylated Liposomal Doxorubicin as a Viable Option	Chung-Liang Li	Guo-Shiou Liao
Satellite Symposium (2)			
12:30-13:10	Luncheon Symposium Refining the Role of Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia	Ming-Shen Dai	Ta-Chung Chao
Optimizing Breast Cancer Treatment: Chemotherapy Sequencing and Evolving Strategies in HR+/HER2- mBC Care			
13:10-13:40	Does the Sequence of Anthracycline and Taxane Matter in Chemotherapy of Early Breast Cancer?	Hsu-Huan Chou	Liang-Chih Liu
13:40-14:10	Filling the Gap after CDK4/6 Inhibitor: The Evolving Treatment Landscape of Patients with HR+/HER2- mBC	Ching-Hung Lin	Hsien-Tang Yeh
14:10-14:30	Coffee Break		
Supplementary Breast Cancer Care: Bone Health and Biosimilar Clinical Trials			
14:30-15:00	Bone Health and Orthopedic Risk Management in Metastatic Breast Cancer Patients	Po-Hsiang Huang	Yao-Lung Kuo
15:00-15:30	Current Experience and Future Perspective in Conducting Biosimilar Clinical Trials in Taiwan	Chiun-Sheng Huang	Shou-Tung Chen
Early Breast Cancer: Sequential Adjuvant Therapy and MRI in Neoadjuvant Therapy			
15:30-16:00	How to Sequence Treatment therapies in HR+ and LN+ EBC	Yi-Fang Tsai	Shen-Liang Shih
16:00-16:30	Do We Need MRI Study Before and After Neoadjuvant Chemotherapy?	Si-Wa Chan	Chih-Chiang Hung
16:30-16:50	Closing	Shou-Tung Chen	